Non-invasive skin phenotyping DERMATACT
11 Monate 4 Wochen her #1
The company Serend-ip offers an objective phenotyping for assessing skin...
Diseases of the skin are often multifactorial and chronic. Visible symptoms are considered an epiphenomenon of an internal cause. Nevertheless, clinical diagnostics still rely mainly on inspection.
The company Serend-ip offers an objective phenotyping for assessing skin status exceeding the optical resolution limits (DERMATACT). Non-lesional areas are sufficient for significant results.
Patient samples are obtained non-invasively using tape-strips and shipped to our lab. Atomic Force Microscopy (AFM) records the topography of adhering corneocytes without any sample processing. Cellular nano-structures are quantitated automatically by computer vision. The ultrastructure count -called Dermal Topographic Index (DTI)- relates to skin barrier function and/ or inflammation. The DTI correlates well to clinical scores, but extends dermatological perception into the non-visible range thanks to higher sensitivity. Hence, clinical testing of pharmaceutic therapies, cosmetic products or skin irritants is performed at higher accuracy - saving costs through minimizing study cohorts or abbreviating time schedules. The DERMATACT-assay is offered as a lab service. Scientific cooperation and commercial distribution partners are sought for.
1: Franz J, Beutel M, Gevers K, Kramer A, Thyssen JP, Kezic S, Riethmüller C. Nanoscale alterations of corneocytes indicate skin disease. Skin Res Technol. 2015 Jun 22. doi: 10.1111/srt.12247. 2: Riethmuller C, McAleer MA, Koppes SA,...., Irvine AD, Kezic S. Filaggrin breakdown products determine corneocyte conformation in patients with atopic dermatitis. J Allergy Clin Immunol. 2015 Dec; 136(6):1573-1580.e2. doi: 10.1016/j.jaci.2015.04.042.